Clonal Architecture of ASXL1-mutated Myelofibrosis

Sex: All

Ages: 18 Years – N/A

Phase: NA

Enrollment: 50

Sponsor: University Hospital, Angers

Summary

Prospective study to decipher the clonal architecture of ASXL1-mutated primary and secondary myelofibrosis and its impact on prognosis

Eligibility Criteria

Inclusion Criteria:Adults (age ≥18 years),Affiliated to the national social security system,ASXL1 mutated primary or secondary myelofibrosis,Signed the consent to participate in the study,Included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM).Exclusion Criteria:Patient with another active hematological disease or cancer at the time of diagnosis,Person subject to legal protection scheme or incapable of giving consent.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05710211). StuddyBuddy aggregates publicly available trial information.